Approximately two years ago, important research funded by Cystic Fibrosis Trust showed that a type of non-tuberculous mycobacteria (NTM) can be transmitted between individuals with cystic fibrosis. As this week is International Infection Prevention Week, we’re giving you an update on how this research has progressed since then.
Hundreds of researchers around the world are investigating genetic therapies for cystic fibrosis (CF). Genetic therapies offer the potential of being able to treat everyone with CF, including those who can't benefit from CFTR modulators. Earlier this month we announced funding for a Strategic Research Centre (SRC) grant on developing gene editing therapies, a type of genetic therapy. Here we take a closer look at how gene editing and other types of genetic therapy work and how they could benefit people with cystic fibrosis.
Learn about the different ways that cystic fibrosis (CF) affects the pancreas and digestive system, including meconium ileus and gastro-oesophageal reflux disease (GORD).
Over-active inflammation is a major contributor to cystic fibrosis (CF)-related lung damage, but not enough is known about what causes it or how it can be treated. In a Trust-funded study at the University of Leeds, researchers have discovered that Orkambi and Symkevi can reduce inflammation in people with CF, and have developed ways to assess the anti-inflammatory effects of future CF treatments. Following our recent Research Blast on inflammation, here we describe the study in more detail.
Antibiotic resistance is the result of decades of overusing antibiotics, and the effects could be potentially devastating for people who rely on them on a regular basis, such as people with cystic fibrosis.
Find out the results of a recent project to discover the CF community's priorities for research and what Cystic Fibrosis Trust is doing to address those issues in this blog by Dr Janet Allen, Director of Strategic Innovation.
Cystic Fibrosis Trust is proud to announce the new Clinical Trials Accelerator Platform, a £3 million investment to encourage faster access to better treatments for people living with cystic fibrosis in the UK.
Cystic Fibrosis Trust’s latest flagship programme gathers momentum in the mission to increase awareness and understanding of clinical trials for cystic fibrosis.
